Korean AI healthcare companies are gearing up to showcase their technologies at Arab Health 2025, the Middle East’s largest medical exhibition, which runs Monday to Thursday at the Dubai World Trade Centre. 

Now in its 50th year, the event will feature over 4,000 exhibitors from 180 countries and is expected to draw approximately 100,000 attendees, offering a platform for businesses to showcase innovations in healthcare.

For Korean firms, the Middle East represents a growing opportunity.

Deepnoid, which opened a branch in Dubai last October, sees the region as a key market for its AI-driven healthcare and security solutions. 

While the company is not exhibiting this year, a Deepnoid official noted, “There’s considerable interest in advanced Korean solutions. Regions with advanced healthcare infrastructure, like the Middle East, provide fertile ground for our cutting-edge medical AI technologies.”

VUNO is making its debut in the region by presenting VUNO Med-DeepCARS, an AI-based tool designed to predict cardiac arrest risk. The product is currently used in over 110 hospitals in Korea and is undergoing FDA approval in the United States.

"Although we are not fully established in the region yet, we see this market as critical for the future of AI medical devices,” said a VUNO official. The company plans to use the event as a stepping stone to establish partnerships and expand its presence in the region. Unlike its previous showcases, which focused on medical imaging, VUNO is highlighting its bio-signal products at this year’s exhibition.

Neurophet, known for its AI-based brain disease diagnostics, will also make its first appearance at Arab Health. The company plans to present Neurophet AQUA AD, a tool for monitoring dementia treatment effects, and Neurophet AQUA, software for neurodegeneration analysis that recently gained FDA clearance. “We aim to meet with local buyers and identify new distributors in the region,” said CEO  Been Jun-kil.

Mediwhale will present Dr. Noon CVD, an AI-powered retinal imaging tool for assessing cardiovascular and metabolic disease risk. The company entered the Middle East market last November by signing an agreement with GluCare, a Dubai-based diabetes management clinic, to supply the technology. Positioned as a stepping stone for broader regional and global expansion, Mediwhale has also extended its reach into Europe and Southeast Asia. The company is now pursuing FDA approval, expected by 2026, as part of its plan to enter the U.S. market.